This article is a correction to:
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
Shuqun Li1,2†Junyi Wu1,3†
Jiayi Wu1,3†
Yangkai Fu1
Zhenxin Zeng1
Yinan Li1
Han Li1
Weijia Liao2*
Maolin Yan1,3*- 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- 2Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
- 3Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China
By Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W and Yan M (2023) Front. Immunol. 14:1109771. doi: 10.3389/fimmu.2023.1109771
In the published article, there was an error in Table 2 as published. “Abnormal pain” should be “Abdominal pain”. The corrected Table 2 and its caption “Treatment-related adverse events” appear below.
TABLE 2
Table 2 Treatment-related adverse events.
In the published article, there was an error. The external validation cohort patients should be 67.
A correction has been made to Materials and methods, Patients and study design, Paragraph 1. This sentence previously stated:
“The external validation cohort (n = 68) included patients from Zhangzhou Municipal Hospital of Fujian Province, Fujian Medical University Union Hospital, and the First Affiliated Hospital of Xiamen University.”
The corrected sentence appears below:
“The external validation cohort (n = 67) included patients from Zhangzhou Municipal Hospital of Fujian Province, Fujian Medical University Union Hospital, and the First Affiliated Hospital of Xiamen University”
In the published article, there was an error. The ORR should be 60.9% and C-index in test cohort should be 0.800.
A correction has been made to Abstract, Results, Paragraph 1. This sentence previously stated:
“The ORR was 60.7% and the risk of early ORR was independently predicted by AFP, portal vein tumor thrombus (PVTT), tumor number, and size in both the training (C-index = 0.853) and test (C-index = 0.731) cohorts.”
The corrected sentence appears below:
“The ORR was 60.9% and the risk of early ORR was independently predicted by AFP, portal vein tumor thrombus (PVTT), tumor number, and size in both the training (C-index = 0.853) and test (C-index = 0.800) cohorts.”
In the published article, there was an error. The ORR should be 60.9%.
A correction has been made to Results, 3.1 Baseline features, Paragraph 1. This sentence previously stated:
“The 3 months ORR of the entire cohort was 60.7%, comprising 147 males and 22 females, respectively.”
The corrected sentence appears below:
“The 3 months ORR of the entire cohort was 60.9%, comprising 147 males and 22 females, respectively.”
In the published article, there was an error. The ORR should be 60.9%.
A correction has been made to Discussion, Paragraph 1. This sentence previously stated:
“The early ORR in all u-HCC cohorts was 60.7%.”
The corrected sentence appears below:
“The early ORR in all u-HCC cohorts was 60.9%.”
In the published article, there was an error. The C-index in test cohort should be 0.800.
A correction has been made to Discussion, Paragraph 2. This sentence previously stated:
“An external cohort also calibrated the nomogram, with a high concordance index of 0.731.”
The corrected sentence appears below:
“An external cohort also calibrated the nomogram, with a high concordance index of 0.800.”
In the published article, there was an error. The C-index in test cohort should be 0.800.
A correction has been made to Results, 3.4 Model performance and validation, Paragraph 1. This sentence previously stated:
“The C-index was 73.13% (95% CI, 63.52%−87.83%, Figure 3)”
FIGURE 3
Figure 3 .
The corrected sentence appears below:
“The C-index was 80.00% (95% CI, 63.52%−87.83%, Figure 3)”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: unresectable hepatocellular carcinoma, TACE, levantinib, anti-PD-1 antibody, immunotherapy, nomogram
Citation: Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W and Yan M (2023) Corrigendum: Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Front. Immunol. 14:1187423. doi: 10.3389/fimmu.2023.1187423
Received: 16 March 2023; Accepted: 27 March 2023;
Published: 11 April 2023.
Edited and Reviewed by:
Zhangjun Cheng, Southeast University, ChinaCopyright © 2023 Li, Wu, Wu, Fu, Zeng, Li, Li, Liao and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maolin Yan, yanmaolin74@163.com; Weijia Liao, liaoweijia288@163.com
†These authors share first authorship